A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

NCT06192108 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication orforglipron compared to dapagliflozin in adults with type 2 diabetes who do not have adequate blood sugar control while taking metformin.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 962 people

Who can join Ages 18+ · all sexes

Timeline Started 2024-01 · est. completion 2025-09

Where 74 sites · China, Germany, Mexico, Poland, Taiwan, United States

What this study is testing ClinicalTrials.gov NCT06192108 ↗

Description as written by the study sponsor.

The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally
Dapagliflozin Drug

Administered orally

Main thing measured	Change from Baseline in Hemoglobin A1c: (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06192108 ↗